BioSpace News Archive

George Chen left AstraZeneca after seven years to pursue his own line of oncology and immunology R&D.

Immunotherapies are about to get safer, more effective, and even more accessible with the new biotech’s novel approach.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it has received final reimbursement pricing of $2,753 from Palmetto MolDx for AlloSure Heart.

Tulip Medical has sponsored and funded a new FDA Oversight Trial that seeks to restore respiratory function in adults who have suffered lung damage from the COVID-19 virus.

New $500K, four-month competition aims to accelerate use of artificial intelligence to minimize coronavirus infection cases while reducing the economic cost of lockdowns

Late-breaking data presented at AHA 2020 Scientific Sessions and published simultaneously in Circulation

Initial findings show potential for material short-term annual savings of up to $5,000 per cardiovascular patient when treated for sleep apnea

ConcertAI announced a multi-year collaboration with Novartis to advance research-grade real-world data (RWD) and advanced analytic technologies to support decision-making across the full scope of Novartis’ oncolog

Initial Appointments Include Internationally Recognized Experts: Fred D. Lublin, M.D.; Bruce E. Sands, M.D., M.S.; Jerrold R. Turner, M.D., Ph.D. and Paul J. Utz, M.D.

Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs